The in vivo activity of
BO-3482, which has a dithiocarbamate chain at the C-2 position of 1beta-methyl-carbapenem, was compared with those of
vancomycin and
imipenem in murine models of
septicemia and thigh
infection with methicillin-resistant Staphylococcus aureus (MRSA). Because
BO-3482 was more susceptible than
imipenem to renal
dehydropeptidase I in a kinetic study of hydrolysis by this renal
enzyme, the therapeutic efficacy of
BO-3482 was determined during coadministration with
cilastatin. In the
septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of
body weight for
BO-3482; 5.56, 2.15, and 1.79 mg/kg for
vancomycin; and >200, >200, and 15.9 mg/kg for
imipenem.
BO-3482 was also as effective as
vancomycin in an MRSA
septicemia model with mice with
cyclophosphamide-induced immunosuppression. In the thigh
infection model with a homogeneous MRSA strain, the bacterial counts in tissues treated with BO-3482-cilastatin were significantly reduced in a dose-dependent manner compared with the counts in those treated with
vancomycin and
imipenem-cilastatin (P < 0.001). These results indicate that BO-3482-cilastatin is as effective as
vancomycin in murine systemic
infections and is more bactericidal than
vancomycin in local-tissue
infections. The potent in vivo activity of BO-3482-cilastatin against such MRSA
infections can be ascribed to the good in vitro anti-MRSA activity and improved pharmacokinetics in mice when
BO-3482 is combined with
cilastatin and to the bactericidal nature of the
carbapenem.